Oravax Medical, a subsidiary of Oramed Pharmaceuticals, has enrolled the first participant for Phase I clinical trial of its oral virus-like particle Covid-19 vaccine in South Africa. The company aims to enrol 24 participants who are yet to receive a vaccine or have contracted the disease. During the trial, two doses of the vaccine will be administered at a gap of three weeks. The study endpoints include assessing the safety and tolerability of the vaccine as well as determining its efficacy.
Moderna’s Covid-19 vaccine Spikevax (mRNA-1273) has secured marketing authorisation in South Korea. The vaccine is manufactured by Samsung Biologics under a previously signed agreement with Moderna. The approval, granted by the Ministry of Food and Drug Safety of Korea, will enable Moderna to distribute the vaccine manufactured in Samsung Biologics’ local facilities across South Korea. It will also enable the company to export Spikevax to other countries.
Malaysia’s health ministry has granted conditional approval for the use of Ronapreve in Covid-19 treatment, reported The Star. The single-dose antibody cocktail, developed by Roche and Regeneron, was indicated for treating individuals above 12 years of age and at risk of developing severe infection. It was further added that Ronapreve can be administered as an injection or infusion in patients who weigh at least 40kg and do not require supplemental oxygen.